Cantor Fitzgerald Predicts ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($1.97) per share for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research note on Wednesday, November 13th.

Acumen Pharmaceuticals Trading Down 4.6 %

NASDAQ ABOS opened at $1.65 on Thursday. The firm’s fifty day moving average price is $1.95 and its 200 day moving average price is $2.46. Acumen Pharmaceuticals has a 12 month low of $1.53 and a 12 month high of $5.09. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market capitalization of $99.13 million, a price-to-earnings ratio of -1.20 and a beta of 0.02.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same quarter in the previous year, the business earned ($0.24) earnings per share.

Insider Activity

In other news, CEO Daniel Joseph Oconnell sold 47,778 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the sale, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. This represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matt Zuga sold 28,902 shares of the stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the sale, the chief financial officer now owns 231,744 shares of the company’s stock, valued at $398,599.68. This trade represents a 11.09 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 131,526 shares of company stock valued at $233,124. 7.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in Acumen Pharmaceuticals in the 2nd quarter valued at $818,000. Franklin Resources Inc. boosted its holdings in shares of Acumen Pharmaceuticals by 5.4% in the third quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company’s stock valued at $8,340,000 after acquiring an additional 181,451 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Acumen Pharmaceuticals during the second quarter worth about $306,000. State Street Corp raised its holdings in Acumen Pharmaceuticals by 18.3% during the third quarter. State Street Corp now owns 516,406 shares of the company’s stock worth $1,281,000 after purchasing an additional 79,841 shares in the last quarter. Finally, Murchinson Ltd. acquired a new stake in Acumen Pharmaceuticals in the second quarter valued at about $136,000. Institutional investors and hedge funds own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.